Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ribomic, Inc. ( (JP:4591) ) just unveiled an update.
Ribomic Inc. reported its non-consolidated financial results for the six months ending September 30, 2025, showing no operating revenues and a net loss. Despite the financial losses, the company maintains a strong equity ratio of 96.1%, indicating a solid financial position, which may reassure stakeholders about its stability amidst ongoing challenges.
More about Ribomic, Inc.
Ribomic Inc. is a company listed on the Tokyo Stock Exchange, operating in the biotechnology sector. It focuses on developing innovative therapeutic solutions, leveraging its expertise in RNA aptamer technology to address unmet medical needs.
Average Trading Volume: 1,733,186
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen4.59B
Learn more about 4591 stock on TipRanks’ Stock Analysis page.